Yesterday Dec. 29, all-time high single day Covid cases were recorded in many high-vaxxed countries:
US 465.7k, France 208.1k,
UK 183.0k, Spain 100.8k,
Italy 98.0k, Greece 28.8k,
Portugal 26.9k, Denmark 22.0k,
Australia 18.2k, Ireland 16.4k.
Canada 49.1k (Dec 27), Switzerland 16.8k (Dec 28).
Instead of the promised: more vax = more protection = less infections,
What happened is the reverse: more vax = less protection = more infections.
We leave 2021 and enter 2022 with even more mutilated immune system, more sickly people.
Meanwhile, some recent reports and studies re vax:
Occurrence and Features of Childhood Myocarditis: A Nationwide Study in Finland
A Report on Myocarditis Adverse Events in the U.S. Vaccine Adverse Events Reporting System (VAERS) in Association with COVID-19 Injectable Biological Products
Jessica Rose PhD, MSc, BSc , Peter A. McCullough MD, MPH
Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older
Anthony Simone, MD1; John Herald, MD1; Aiyu Chen, MPH2; et al
Myocarditis after Covid-19 mRNA Vaccination
Case Report: Acute Fulminant Myocarditis and Cardiogenic Shock After Messenger RNA Coronavirus Disease 2019 Vaccination Requiring Extracorporeal Cardiopulmonary Resuscitation
Lim, Yongwhan et al
Myocarditis-induced Sudden Death after BNT162b2 mRNA COVID-19 Vaccination in Korea: Case Report Focusing on Histopathological Findings
The SARS-CoV-2 Spike protein disrupts human cardiac pericytes function through CD147-receptor-mediated signalling: a potential non-infective mechanism of COVID-19 microvascular disease
SARS-CoV-2 mRNA Vaccination-Associated Myocarditis in Children Ages 12-17: A Stratified National Database Analysis
Tracy Beth Høeg
Management of Myocarditis-Related Cardiomyopathy in Adults
Fauci, Emails, and Some Alleged Science
Phil Magness James R. Harrigan December 19, 2021
Boosted immunity to the common cold might protect children from COVID-19
Jason J. Lavinder & Gregory C. Ippolito
Nature Immunology volume 23, pages8–10 (2022)
22 December 2021
New data show that, compared with adults, children infected by SARS-CoV-2 preferentially activate pre-existing immunity to endemic common-cold coronaviruses that are cross-reactive with SARS-CoV-2, with potential implications for pediatric vaccine strategies.
Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection
Alexander C. Dowell, Megan S. Butler, Elizabeth Jinks, Gokhan Tut, Tara Lancaster, Panagiota Sylla, Jusnara Begum, Rachel Bruton, Hayden Pearce, Kriti Verma, Nicola Logan, Grace Tyson, Eliska Spalkova, Sandra Margielewska-Davies, Graham S. Taylor, Eleni Syrimi, Frances Baawuah, Joanne Beckmann, Ifeanyichukwu O. Okike, Shazaad Ahmad, Joanna Garstang, Andrew J. Brent, Bernadette Brent, Georgina Ireland, Felicity Aiano, Zahin Amin-Chowdhury, Samuel Jones, Ray Borrow, Ezra Linley, John Wright, Rafaq Azad, Dagmar Waiblinger, Chris Davis, Emma C. Thomson, Massimo Palmarini, Brian J. Willett, Wendy S. Barclay, John Poh, Gayatri Amirthalingam, Kevin E. Brown, Mary E. Ramsay, Jianmin Zuo, Paul Moss & Shamez Ladhani Show fewer authors
Nature Immunology volume 23, pages40–49 (2022)
Published: 22 December 2021
Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2
Lihong Liu , Sho Iketani , Yicheng Guo , Jasper F-W. Chan , Maple Wang , Liyuan Liu , Yang Luo , Hin Chu , Yiming Huang , Manoj S. Nair , Jian Yu , Kenn K-H. Chik , Terrence T-T. Yuen , Chaemin Yoon , Kelvin K-W. To , Honglin Chen , Michael T. Yin , Magdalena E. Sobieszczyk , Yaoxing Huang , Harris H. Wang , Zizhang Sheng , Kwok-Yung Yuen & David D. Ho
23 December 2021
We found B.1.1.529 to be markedly resistant to neutralization by serum not only from convalescent patients, but also from individuals vaccinated with one of the four widely used COVID-19 vaccines. Even serum from persons vaccinated and boosted with mRNA-based vaccines exhibited substantially diminished neutralizing activity against B.1.1.529...
Does Omicron Represent the Beginning of the End of COVID-19? South African-led Research Raises a Glimmer of Hope
TrialSite Staff. December 28, 2021
...the study authors discuss their findings: the highly transmissible yet seemingly milder Omicron demonstrated 14 days after enrollment a 14-fold boost in neutralization against Omicron with a 4.4 fold boost of neutralization to the Delta variant.
SARS-CoV-2 Loves the Vaccines
eugyppius. Dec 28 2021
The mRNA vaccines aren’t very safe; they cause a wealth of severe side effects, particularly in the lowest-risk age cohorts. These side effects outweigh the risks of SARS-2 infection for everyone under 40; for those in good health facing the vastly milder Omicron, there is really no reason to be vaccinated. The second dose of Moderna is particularly dangerous for young men.
Bhakdi/Burkhardt pathology results show 93% of people who died after being vaccinated were killed by the vaccine
Steve Kirsch. Dec 29 2021
The vaccines are bad news. Fifteen bodies were examined (all died from 7 days to 6 months after vaccination; ages 28 to 95). The coroner or the public prosecutor didn’t associate the vaccine as the cause of death in any of the cases. However, further examination revealed that the vaccine was implicated in the deaths of 14 of the 15 cases. The most attacked organ was the heart (in all of the people who died), but other organs were attacked as well. The implications are potentially enormous resulting in millions of deaths. The vaccines should be immediately halted.
Pandemic of the Vaccinated: Two Studies Show New Evidence that Covid-19 Vaccines “Cause More Illness than They Prevent”
By Julian Conradson. December 29, 2021 at 7:57pm
Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study
Christian Holm Hansen, Astrid Blicher Schelde, Ida Rask Moustsen-Helm, Hanne-Dorthe Emborg, Tyra Grove Krause, Kåre Mølbak, Palle Valentiner-Branth
... from Danish nationwide databases of vaccine effectiveness (VE) against the novel SARS-CoV-2 Omicron variant (B.1.1.529) up to five months after a primary vaccination series with the BNT162b2 or mRNA-1273 vaccines.
... we found a VE against the Omicron variant of 55.2% (95% confidence interval (CI): 23.5 to 73.7%) and 36.7% (95% CI: 69.9 to 76.4%) for the BNT162b2 and mRNA-1273 vaccines, respectively, in the first month after primary vaccination. However, the VE is significantly lower than that against Delta infection and declines rapidly over just a few months. The VE is re-established upon revaccination with the BNT162b2 vaccine (54.6%, 95% CI: 30.4 to 70.4%).
Covid 61, CCH and CDC Ph full page ads re mandatory vaccination, December 14, 2021
Covid 62, CDC Ph longer draft for the full-page ad, December 15, 2021
Covid 63, No Tricks Zone on vaccine and medical tyranny, December 25, 2021.